DRG Market Assessment reports

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven…

Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-…

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of…

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant…

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of the most dynamic drug…

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to…

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The EGFR and ALK TKIs Tagrisso and…

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include…